Intercept Pharmaceuticals, Inc.

Panmira Pharmaceuticals, LLC

Melissa Rewolinski

Alex Eberlin

Emma Sharp

André Steiner

Heidi Waenerlund Poulsen

Fiona Dubas-Fisher

Emilie Jolibois

Ralf Gross

Andre Steiner

Nicholas Simon Stock

Christopher David King

Kevin Schaab

The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.

Preparation and uses of obeticholic acid

Described herein are methods for the synthesis of 3-[5-(pyridin-2-ylmethoxy)-3-(2-methyl-2-propylthio)-1-[4-(2-methoxypyridin-5-yl)benzyl]-indol-2-yl]-2,2-dimethyl-propionic acid, pharmaceutically acceptable salts, pharmaceutically acceptable solvates thereof. Also described are pharmaceutical compositions suitable for oral administration to a mammal that include, as well as methods of using such oral pharmaceutical compositions for treating respiratory conditions or diseases, as well as other leukotriene-dependent or leukotriene mediated conditions or diseases.

5-lipoxygenase activating protein (FLAP) inhibitor

Growing community of inventors

San Diego, CA, United States of America

Melissa Rewolinski